The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.
Medpage Today on MSN6mon
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLCas first-line therapy for PD-L1-positive, advanced non-small cell lung cancer (NSCLC) in a Chinese trial. In the phase III ...
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for ...
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
SUZHOU, China I March 23, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...
The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback